Document is current

Article History

Received: 12 April 2024

Accepted: 5 September 2024

First Online: 27 September 2024

Ethics approval and consent to participate

: The Cantonal Ethics Committee of the Canton of Zurich in Switzerland reviewed the study protocol, stated that the project does not fall within the scope of the Human Research Act, issued a declaration of no objection (Business Management System for Ethics Committees Number Req-2021-00756) and waived the need for ethical approval. Participants were informed that their responses to the questionnaire would be used for scientific purposes. The participants' consent to participate was implied by their completion of the form and its submission. Participation in the study was voluntary, ensuring anonymity, and without any compensation.

: CBN is an inventor of Visual Patient and Visual Patient Predictive technologies, for which the University of Zurich and Koninklijke Philips N.V. hold patents, patent applications, design protections, and trademarks. Joint-development and licensing agreements exist with Philips Medizin Systeme Böblingen GmbH, Böblingen, Germany; Koninklijke Philips N.V., Amsterdam, The Netherlands; Philips Research/Philips Electronics Nederland BV, Eindhoven, The Netherlands; and Philips USA, Cambridge, MA, USA. Within the framework of these agreements, CBN receives travel support, lecturing and consulting honoraria, and may potentially receive royalties in the event of successful commercialization. CBN is an inventor of Visual Clot technology, with patent applications, design protections, and trademarks held by the University of Zurich. In case of successful commercialization, CBN may receive royalties. CBN is an inventor of Visual Blood technology, for which the University of Zurich holds patent applications and design protections; potential royalties may follow successful commercialization. CBN received travel support, lecturing, and consulting honoraria from Instrumentation Laboratory – Werfen, Bedford, MA, USA. DWT is the first named inventor of Visual Patient and Visual Patient Predictive technologies, for which the University of Zurich and Koninklijke Philips N.V. hold patents, patent applications, design protections, and trademarks. Joint-development and licensing agreements exist with Philips Medizin Systeme Böblingen GmbH, Böblingen, Germany; Koninklijke Philips N.V., Amsterdam, The Netherlands; Philips Research/Philips Electronics Nederland BV, Eindhoven, The Netherlands; and Philips USA, Cambridge, MA, USA. Within the framework of these agreements, DWT receives research funding, travel support, lecturing and consulting honoraria, and may potentially receive royalties in the event of successful commercialization. DWT also holds a position on the Philips Patient Safety Advisory Board. DWT is the first named inventor of Visual Clot technology, with patent applications, design protections, and trademarks held by the University of Zurich. In case of successful commercialization, DWT may receive royalties. DWT is the first named inventor of Visual Blood technology, for which the University of Zurich holds patent applications and design protections; potential royalties may follow successful commercialization. Additionally, DWT received travel support, lecturing, and consulting honoraria from Instrumentation Laboratory – Werfen, Bedford, MA, USA, the Swiss Foundation for Anaesthesia Research in Zurich, Switzerland, and the International Symposium on Intensive Care and Emergency Medicine in Brussels, Belgium. No other funding or competing interests declared. Other authors declare that they have no conflict of interest.